title: Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
abstract: Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity. The tolerability and efficacy of lower starting doses of sorafenib for DTC remain largely unstudied. Methods. We retrospectively examined overall survival, time to treatment failure, time to progression, discontinuation rates, and dose-reduction and interruption rates in patients with metastatic DTC treated with first-line sorafenib outside of a clinical trial. Two patient groups were compared; group 1 received the standard starting dose of 800 mg/day, and group 2 received any dose lower than 800 mg/day. Results. We included 75 adult patients, with 51 in group 1 and 24 in group 2. Mean age at diagnosis was 54 years, and 56% were male. The most common histologies included 43% papillary thyroid cancer of the conventional type, 15% papillary thyroid cancer of the follicular variant, and 15% Hürthle cell carcinoma. Time to treatment failure was 10 months (95% confidence interval [CI]: 5.6-14.3) in group 1 and 8 months (95% CI: 3.4-12.5) in group 2 (p = .56). Median overall survival was 56 months (95% CI: 30.6-81.3) in group 1 and 30 months (95% CI: 16.1-43.8) in group 2 (p = .08). Rates of discontinuation due to disease progression were 79% in group 1 and 91% in group 2, and 21% in group 1 and 9% in group 2 (p = .304) stopped treatment because of toxicity. Dose-reduction rates were 59% and 43% (p = .29), and interruption rates were 65% and 67% (p = .908) in group 1 and group 2, respectively. Conclusion. Efficacy and tolerability of sorafenib in treatment-naïve DTC patients does not appear to be negatively influenced by lower starting daily doses.
authors.affiliation: Departments of Endocrine Neoplasia and Hormonal Disorders and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Ramona
authors.initials: R
authors.lastname: Dadu
authors.forename: Steven G
authors.initials: SG
authors.lastname: Waguespack
authors.forename: Steven I
authors.initials: SI
authors.lastname: Sherman
authors.forename: Mimi I
authors.initials: MI
authors.lastname: Hu
authors.forename: Naifa L
authors.initials: NL
authors.lastname: Busaidy
authors.forename: Camilo
authors.initials: C
authors.lastname: Jimenez
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Habra
authors.forename: Anita K
authors.initials: AK
authors.lastname: Ying
authors.forename: Roland L
authors.initials: RL
authors.lastname: Bassett
authors.forename: Maria E
authors.initials: ME
authors.lastname: Cabanillas
mesh_terms: D018249:Adenoma, Oxyphilic; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002291:Carcinoma, Papillary; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: Adverse events; Dose reduction; Drug interruptions; Overall survival; Time to failure
references.citation: Eur J Endocrinol. 2009 Dec;161(6):923-31
references.pmid: 19773371
references.citation: Ann Oncol. 2005 Oct;16(10):1688-94
references.pmid: 16006586
references.citation: Oncologist. 2007 Apr;12(4):426-37
references.pmid: 17470685
references.citation: J Natl Compr Canc Netw. 2010 Nov;8(11):1228-74
references.pmid: 21081783
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1675-84
references.pmid: 19255327
references.citation: Thyroid. 2009 Nov;19(11):1167-214
references.pmid: 19860577
references.citation: Br J Cancer. 2005 May 23;92(10):1855-61
references.pmid: 15870716
references.citation: J Clin Oncol. 2005 Feb 10;23(5):965-72
references.pmid: 15613696
references.citation: J Clin Endocrinol Metab. 2013 Jan;98(1):31-42
references.pmid: 23185034
references.citation: Clin Cancer Res. 2005 Aug 1;11(15):5472-80
references.pmid: 16061863
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Thyroid. 2011 Feb;21(2):119-24
references.pmid: 21186953
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Chin Clin Oncol. 2014 Mar;3(1):8
references.pmid: 25842086
references.citation: Eur J Endocrinol. 2011 Aug;165(2):315-22
references.pmid: 21566072
references.citation: Eur J Endocrinol. 2012 Nov;167(5):643-50
references.pmid: 22918300
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4714-9
references.pmid: 18541894
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530